cb-NIPT 

cb-NIPT single cell non-invasive prenatal gene detection is the world's first new generation of non-invasive prenatal detection service based on fetal cells in maternal peripheral blood.

As early as 10-12 weeks of pregnancy, 20ml of venous blood of pregnant women can be extracted, and the rare cell capture platform of full-automatic fluorescent staining proprietary to hetronics can be used to separate trace, complete and active circulating fetal cells. According to the whole genome information of single cell, the risk rate of fetal heritage disease can be determined. It is the most comprehensive, accurate and safe product inspection service known at present. At the same time, the technology can also be applied to prenatal paternity test.

Technical principle

Fetal genetic material will enter the maternal blood through the placenta. At present, there are two sources of non-invasive methods to obtain fetal genetic material: fetal free DNA (cffDNA) in maternal peripheral blood and fetal cells in maternal blood.

The proportion of circulating fetal cells in maternal peripheral blood is very low, only 0.5 cells per ml on average. Using unipicker ® single cell capture platform independently developed by hzobio, it is the first time to achieve high success rate of fetal cell capture.

Technological advantage

• Exact: eliminate maternal DNA interference
• Precision: one billionth of trace single cell capture
• Comprehensive: covering all known genetic disease tests
• Simple: only 20ml of pregnant women's venous blood needs to be collected
• Accuracy: the detection rate of common genetic diseases is more than 99%
• Safety: venous blood sampling, fetal safety, non-invasive